Research ArticleNuclear Oncology
Radioimmunotherapy for Breast Cancer Using Indium-lll/Yttrium-90 BrE-3: Results of a Phase I Clinical Trial
Sally J. DeNardo, Elissa L. Kramer,, Robert T. O'Donnell, Carol M. Richman,, Qansy A. Salako, Sui Shen, M. Noz, Stephen D. Glenn, Roberto L. Ceriani and Gerald L. DeNardo
Journal of Nuclear Medicine August 1997, 38 (8) 1180-1185;
Sally J. DeNardo
Elissa L. Kramer,
Robert T. O'Donnell
Carol M. Richman,
Qansy A. Salako
Sui Shen
M. Noz
Stephen D. Glenn
Roberto L. Ceriani


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Radioimmunotherapy for Breast Cancer Using Indium-lll/Yttrium-90 BrE-3: Results of a Phase I Clinical Trial
Sally J. DeNardo, Elissa L. Kramer,, Robert T. O'Donnell, Carol M. Richman,, Qansy A. Salako, Sui Shen, M. Noz, Stephen D. Glenn, Roberto L. Ceriani, Gerald L. DeNardo
Journal of Nuclear Medicine Aug 1997, 38 (8) 1180-1185;
Radioimmunotherapy for Breast Cancer Using Indium-lll/Yttrium-90 BrE-3: Results of a Phase I Clinical Trial
Sally J. DeNardo, Elissa L. Kramer,, Robert T. O'Donnell, Carol M. Richman,, Qansy A. Salako, Sui Shen, M. Noz, Stephen D. Glenn, Roberto L. Ceriani, Gerald L. DeNardo
Journal of Nuclear Medicine Aug 1997, 38 (8) 1180-1185;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Radioiodinated versus Radiometal-Labeled Anti-Carcinoembryonic Antigen Single-Chain Fv-Fc Antibody Fragments: Optimal Pharmacokinetics for Therapy
- Enhancement of the Therapeutic Index: From Nonmyeloablative and Myeloablative toward Pretargeted Radioimmunotherapy for Metastatic Prostate Cancer
- Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu?
- Current Status of Therapy of Solid Tumors
- A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer
- Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma
- Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy
- Radiolabeled Monoclonal Antibodies Specific to the Extracellular Domain of Prostate-Specific Membrane Antigen: Preclinical Studies in Nude Mice Bearing LNCaP Human Prostate Tumor
- Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for Metastatic Prostate Cancer
- Radiosensitization of Tumor-targeted Radioimmunotherapy with Prolonged Topotecan Infusion in Human Breast Cancer Xenografts
- Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3
- Radioimmunotherapy of Human Colon Cancer Xenografts Using a Dimeric Single-Chain Fv Antibody Construct